Thrombosis in thrombocythemic Ph‐ myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide-Reference-Cited by-同舟云学术

Thrombosis in thrombocythemic Ph‐ myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

Published:2015-04-21 Issue:1 Volume:96 Page:98-106
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Schwarz Jiří¹²,Ovesná Petra³,Černá Olga⁴,Kissová Jarmila⁵,Soukupová Jacqueline Maaloufová¹,Brychtová Yvona⁶,Doubek Michael⁶,Červinek Libor⁶,Cmunt Eduard⁷,Dulíček Petr⁸,Campr Vít¹⁹,Křen Leoš¹⁰,Penka Miroslav⁵,

Affiliation:

1. Institute of Hematology and Blood Transfusion Prague Czech Republic

2. Institute of Clinical and Experimental Hematology 1st Medical Faculty Charles University Prague Czech Republic

3. Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

4. Internal Hematology Clinic Faculty Hospital Královské Vinohrady Prague Czech Republic

5. Department of Clinical Hematology Faculty Hospital Brno Masaryk University Brno Czech Republic

6. Department of Internal Medicine – Hematology and Oncology Faculty Hospital Brno Masaryk University Brno Czech Republic

7. Department of Clinical Hematology of the 1st Department of Internal Medicine 1st Medical Faculty Charles University Prague Czech Republic

8. 4th Department of Internal Medicine – Hematology Faculty Hospital Charles University Hradec Králové Czech Republic

9. Institute of Pathological Anatomy 2nd Medical Faculty Faculty Hospital Motol Charles University Prague Czech Republic

10. Department of Pathology Faculty Hospital Brno Masaryk University Brno Czech Republic

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12554

Reference43 articles.

1. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment;Murphy S;Semin Hematol,1997

2. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

3. Clinical and Pathological Criteria for the Diagnosis of Essential Thrombocythemia, Polycythemia Vera, and Idiopathic Myelofibrosis (Agnogenic Myeloid Metaplasia)

4. Diagnosis and treatment of BCR/ABL‐negative myeloproliferative diseases – principles and rationale of CZEMP recommendations;Schwarz J;Vnitř Lék,2011

5. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review;Current Issues in Molecular Biology;2024-08-02

2. Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review;Biomedicines;2023-01-28

3. Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms;Open Life Sciences;2023-01-01

4. Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group;European Journal of Haematology;2022-06-24

5. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet;The Lancet Haematology;2021-09